Solvay, Par Executives Told to Comply With Subpoena
This article is for subscribers only.
Current and former executives of drugmakers including Solvay SA must comply with a subpoena in a probe into whether they colluded to delay lower-cost copies of the company’s Androgel testosterone treatment.
The U.S. Court of Appeals in Washington today upheld a lower court’s ruling and rejected the appeal by Scott Tarriff, a former chief executive officer of Par Pharmaceutical Cos., and other officials who objected to being videotaped while giving testimony.